SCHEMBL1054471

SCHEMBL1054471

CCC(=O)C(C#N)c1ccc(OC)c(OC)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.49
LMNA P02545 3/20 0.49
MAPT P10636 3/20 0.49
HTT P42858 2/20 0.49
KDM4E B2RXH2 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
ACHE P22303 4/20 0.46
TSHR P16473 1/20 0.45
RAB9A P51151 1/20 0.45
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
PPARA Q07869 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
ELANE P08246 1/20 0.43
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1055546 0.87 ALDH1A1 (0.48) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL11812824 0.84 ACHE (0.54) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL5744359 0.84 ALDH1A1 (0.51) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL16946659 0.83 ALDH1A1 (0.50) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL7036238 0.82 ALDH1A1 (0.51) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL11814682 0.81 ACHE (0.50) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL1054967 0.81 ALDH1A1 (0.47) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL5634134 0.78 PPARG (0.53) ALDH1A1LMNAL3MBTL1ACHETSHR
SCHEMBL1056618 0.78 CYP1A2 (0.48) ALDH1A1LMNAMAPTHTTKDM4E
SCHEMBL27950439 0.77 ALDH1A1 (0.47) ALDH1A1LMNAMAPTHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872014-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-01-18 US disclosed
EP-1648455-A4 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-03-04 EP disclosed
US-20070032515-A1 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2007-02-08 US disclosed
EP-1648455-A2 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-04-26 EP disclosed
WO-2005009389-A2 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-02-03 WO disclosed
EP-0466640-B1 Alpha-carbonylphenylacetonitrile derivatives as stabilizers for organic substances CIBA GEIGY AG (CH) 1995-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032515-A1 Anaplastic lymphoma kinase modulators and methods of use ALK, MALT1, BCL6 ALDH1A1 1285/4885LMNA 973/4885MAPT 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.